There are 412 resources available
1465P - Clinical impact of proton pump inhibitor on the therapeutic outcome of non-small cell lung cancer patients with PD-L1 TPS ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor plus chemotherapy: A retrospective multicenter cohort study
Presenter: Hayato Kawachi
Session: Poster session 20
1042P - INSIGHT 003 evaluating feasibility of eftilagimod alpha (soluble LAG-3) combined with first-line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas
Presenter: Akin Atmaca
Session: Poster session 19
1339P - Real-world experience of dacomitinib in mEGFR Advanced NSCLC: A single centre experience
Presenter: Bivas Biswas
Session: Poster session 19
1434P - Machine learning features derived from spatial interaction of immune cell families are associated with survival in NSCLC patients post-immunotherapy
Presenter: sara arabyarmohammadi
Session: Poster session 20
2356P - The role of pathological features in predicting prognosis of patients with advanced RET-positive NSCLC
Presenter: Arianna Marinello
Session: Poster session 16
1388P - Real-world prognostic value of RET fusions in advanced non-small cell lung cancer (aNSCLC)
Presenter: Shirish Gadgeel
Session: Poster session 20
2266P - IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort
Presenter: Marie Morfouace
Session: Poster session 08
1504TiP - HARMONi: Randomized, double-blind, multi-center, phase III clinical study of ivonescimab or placebo combined with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have progression following EGFR-TKI treatment
Presenter: WenFeng Fang
Session: Poster session 21